High-dose cyclophosphamide for aplastic anemia and autoimmunity

Research output: Contribution to journalReview articlepeer-review

Abstract

High-dose cyclophosphamide was developed as a conditioning regimen for allogeneic bone marrow transplantation. Later, it was discovered that high-dose cyclophosphamide spares early hematopoietic stem cells because of their relatively high levels of the enzyme aldehyde dehydrogenase; thus, high-dose cyclophosphamide is a potent immunosuppressive agent, but nonmyeloablative. Recent reports demonstrate that high-dose cyclophosphamide without bone marrow transplantation induces durable treatment-free remissions in severe aplastic anemia and a variety of other autoimmune disorders; however, there is lingering concern about the safety of this approach.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalCurrent opinion in oncology
Volume14
Issue number2
DOIs
StatePublished - Mar 28 2002
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'High-dose cyclophosphamide for aplastic anemia and autoimmunity'. Together they form a unique fingerprint.

Cite this